Please login to the form below

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

The decision comes after a clinical study suggested that patients given Xofigo in combination with Zytiga (abiraterone acetate) and prednisone/prednisolone could be at risk of dying earlier and had more

Latest news

Daily Brief: NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

families. “We firmly believe that the clinical effectiveness demonstrated in the multinational, Phase 3 LATITUDE study, means that abiraterone plus ADT should be made available routinely to NHS patients that need
EMA starts review of Xtandi in non-metastatic prostate cancer

At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.
J&J’s Erleada first US drug for non-metastatic prostate cancer

momentum before Zytiga (abiraterone acetate) - its current blockbuster medicine for CRPC - faces generic competition in the US, which accounted for around half of the drug’s $2.5bn in sales in
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

At the moment Xtandi, in common with a rival therapy from Johnson &Johnson called Zytiga (abiraterone acetate), is only prescribed for men with advanced CRPC that has spread and no longer ... Pfizer’s chief operating officer Albert Bourla told analysts
EC expands Janssen’s prostate cancer drug reach

Janssen has chalked up a significant win in the European market following a ruling on its prostate cancer drug Zytiga (abiraterone acetate), receiving the go-ahead to add an earlier stage

More from news
Approximately 5 fully matching, plus 65 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

outperforming J&J's Zytiga [abiraterone].
Taking a strategic approach

But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
Pharma deals during October 2013

AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
Interview: Cesar Rodriguez, Janssen

Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “ a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Consumer Health Account Director: Circa £60, 000 Gym and More

Director, Market Access / HEOR - North-West: Negotiable

Account Manager / Account Director: Competative

Associate Director, Market Access & HEOR – North-West: Negotiable

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Medical Writers: Competitive Salary and Benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Director: Excellent benefits

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Senior Account Executive, London, Medical Communications: Excellent package

Consultant Health Economics - London / Oxford: Negotiable

Medical/ Scientific Director: Salary TBC

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

New Business Director - PR: Competitive Salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Production Manager – Healthcare Communications: DOE

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Senior Medical Writer: Great salary and benefits

Senior Systematic Review Analyst - Oxford: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Subscribe to our email news alerts

PMHub

Add my company

IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...